SYSTEMATIC REVIEW

Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis

Maria Elena Flacco1 | Cecilia Acuti Martellucci1 | Valentina Baccolini2 | Corrado De Vito2 | Erika Renzi2 | Paolo Villari2 | Lamberto Manzoli3

1Department of Environmental and Preventive Sciences, University of Ferrara, Ferrara, Italy
2Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
3Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Correspondence
Lamberto Manzoli, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Email: lmanzoli@post.harvard.edu

Abstract

Introduction: A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection.

Methods: We searched MedLine, Scopus and preprint repositories for cohort studies evaluating the onset of new infections among baseline SARS-CoV-2-positive subjects. Random-effect meta-analyses of proportions were stratified by gender, exposure risk, vaccination status, viral strain, time between episodes, and reinfection definition.

Results: Ninety-one studies, enrolling 15,034,624 subjects, were included. Overall, 158,478 reinfections were recorded, corresponding to a pooled rate of 0.97% (95% CI: 0.71%–1.27%), with no substantial differences by definition criteria, exposure risk or gender. Reinfection rates were still 0.66% after ≥12 months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3 months of Omicron wave, the reinfection rates reached 3.31%. Overall rates of severe/lethal COVID-19 were very low (2–7 per 10,000 subjects according to definition criteria) and were not affected by strain predominance.

Conclusions: A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low. The risk–benefit profile of multiple vaccine doses for this subset of population needs to be carefully evaluated.
1 | INTRODUCTION

After the first documented case on August 2020 in Hong Kong,1 an increasing number of field studies estimated the rate of SARS-CoV-2 reinfections after a primary episode.2–27 Although the reported rates have been consistently low, the results differed according to the adopted definition of reinfection, setting, pandemic period, follow-up duration and uncertainties remain on the risk of developing a severe COVID-19 disease after a reinfection.17,20,28 Moreover, the rapid spread of the SARS-CoV-2 Omicron variant (B.1.1.529)29 has posed additional concerns on the degree of protection conferred by prior infections.30,31

As a precise estimate of the frequency and severity of reinfections would be critical to predict the course of the pandemic and optimize restriction and vaccination policies for the hundreds of millions of subjects who recovered from a SARS-CoV-2 infection,32–34 we carried out a meta-analysis of the available prospective observational evidence to provide a pooled estimate of the risk of SARS-CoV-2 reinfection and severe and lethal COVID-19. Reinfection rates were also computed separately for each gender, exposure risk, vaccination coverage, definitions of reinfection and predominant viral strain.

2 | METHODS

The reporting of this meta-analysis was guided by the standards of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 Statement.35 We extracted data from cohort studies evaluating the onset of a new SARS-CoV-2 infection (either asymptomatic or symptomatic) among subjects of all ages with a prior positive SARS-CoV-2 baseline status.

We searched MedLine and Scopus databases, up to 30 June 2022 using the following search strategy, without language restrictions: (coronavirus* or coronavirus* or coronavirinae* or Coronavirus* or Coronavirus* or Wuhan* or Hubei* or Huanan or ‘2019-nCoV’ or 2019nCoV or nCoV2019 or ‘nCoV-2019’ or ‘COVID-19’ or COVID19 or ‘CORVID-19’ or CORVID19 or ‘WN-CoV’ or WNCov or ‘HCoV-19’ or HCoV19 or CoV or ‘2019 novel*’ or Ncov or ‘n-cov’ or ‘SARS-CoV-2’ or ‘SARS-CoV-2’ or ‘SARS-CoV2’ or ‘SARS-CoV2’ or SARS-CoV19 or ‘SARS-Cov19’ or ‘SARS-Cov-19’ or ‘SARS-Cov-19’ or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*) AND (reinfection* or re-infection* or second episode or recurrence* or recrudescence* or relapse* or RCOVID19).36 The references of the reviews and retrieved articles were also screened for additional pertinent papers. Given that several relevant clinical databases have been shared in public preprint repositories in the context of a public health emergency, we also searched for potential studies among those submitted in medRxiv.org.37 In case of re-analyses published from the same cohort, we extracted the data of the publication with the longer follow-up or, if the length of follow-up was identical, with the largest sample size.

Each included article was independently evaluated by three reviewers (CAM, VB and ER), who extracted the main study characteristics (first author, publication year, study design, population, overall sample, mean age and gender distribution of the participants, length of follow-up, dominant variant, vaccination coverage (if under-way), protocol of evaluation of SARS-CoV-2 (re)infection, minimum time lag between primary and secondary positive episodes) and the raw numbers of: (a) SARS-CoV-2 reinfections (asymptomatic infections or mild diseases, with fever or malaise plus at least one of the followings: sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis and diarrhoea with no hospital admission); (b) severe COVID-19 diseases (requiring hospital admission with no use of an intensive care unit); (c) subjects with very severe/lethal COVID-19 disease (requiring admission in an intensive care unit and/or causing death).11 In case of discrepancies in data extraction, a fourth author was contacted (MEF), and consensus achieved through discussion.

The first infection was defined by the presence of: (a) a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test; and/or (b) a baseline positive serology, investigated with the use of an anti-trimeric spike IgG enzyme-linked immunosorbent assay (ELISA).38

In accordance with the CDC criteria,39 a reinfection was defined by the presence of:

a. two positive PCR samples detected ≥45 days apart with ≥1 negative RT-PCR test collected between the first and second episode40 and/or confirmation of infection with two different phylogenetic strains by viral genomic sequencing28;
b. two positive PCR samples detected ≥45 days apart in subjects with a symptomatic second episode or in close contact with a laboratory-confirmed COVID-19 case39;
c. a positive PCR test ≥45 days after the first positive serology (detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay—ELISA).38,39

When a study adopted a time lag between two positive episodes <45 days, we conservatively extracted and included only the cases with a new positive RT-PCR occurring ≥45 days after the first episode, unless other evidences of reinfection (negative PCR or different genome sequence) were available.

We used random-effect meta-analyses of proportions to combine data and obtain summary estimates of the incidence of (a) SARS-CoV-2 re-infection, (b) severe COVID-19 and (c) very severe/lethal COVID-19. We computed the pooled rate of each outcome twice: (1) using ≥45 days as the minimum time lag between two positive episodes; (2) adopting a more stringent time lag of ≥90 days.39 Additionally, when data were available, we performed several stratified analyses and computed separate estimates by (a) gender; (b) exposure risk (health care workers vs. the general population); (c) vaccination status (unvaccinated; coverage of 25–50% of the sample; coverage of 100%); (d) dominant viral strain (Alpha or Beta; Delta; Omicron); (e) months between first episode and reinfection (<6; 6–11; ≥12); (f) risk of reinfection misclassification. As the definition of reinfection has evolved over time,28 some studies did not verify the presence of an intermediate negative RT-PCR sample or viral genomic sequencing data during the ≥45 days between the positive swabs. Since a new positive RT-PCR in a subject with a previously documented infection may indicate reinfection, but also persistence of nonviable RNA after the primary infection— or relapse,41 these studies were considered at risk of misclassification bias. All analyses were carried out using Stata, version 13.1 (Stata Corp., College Station, TX, 2013).

3 | RESULTS

Of the 3282 papers initially retrieved, we included 91 cohort studies evaluating the onset of reinfection, severe and very severe/lethal COVID-19 among 15,034,624 previously infected subjects (Figure 1), either among health care workers (27 publications; n = 37,5984,8,9,15,17,24,26,38,42–59) or in the general population (67 publications; n = 14,997,0264,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102) as the same publication provided separate data for both staff and residents of long-term care facilities,17,49 or adopted different approaches to evaluate the baseline positivity in two separate groups of subjects.4 finally provided individual participants data.7 This led to a total of 94 datasets included in the analyses.

As shown in Table S1, most of the included studies (n = 43) were carried out in Europe 2,4–10,12,15,17,18,21,24,26,36,38,44,46–51,58,66,69,71,72,75,78,81,85–88,91–93,95,99,102 24 in the USA,20,22,23,25,42,43,57,59,63,67,77,79,82–84,89,90,97,98,103,105–107 18 in Asia 3,16,19,27,45,52–54,56,60,62,64,65,70,73,74,100,101 and the remaining six in South America or South Africa.61,68,80,94,96,104 The mean age of the participants ranged from 15 to 87 years, and the average follow-up ranged from 29 to 371 days. Overall, 38 publications strictly followed the CDC criteria to identify the reinfections and were classified at low risk of misclassification bias.10,16,19,20,22–24,26,44,45,48–50,54,56,58,59,68,71,72,75,78,86,89–91,94,99,100,102 All but five studies (n = 3,854,961)66,71,88,91,96 were completed before the emergence of BA.1/B.1.1.529 (Omicron) variant. A total of 52 out of the 91 included studies reported an incidence of reinfections below 1%, and 47 an absolute risk of severe or lethal COVID-19 below 0.1%.

Overall, a total of 158,478 reinfections were recorded among the 15,034,624 subjects with a previous infection,2–10,12,13,15–27,36,38,42–107 corresponding to a pooled rate of 0.97% (95% CI: 0.71%–1.27%—Table 1; Figure 2). The summary rate of reinfection rose to 1.07% (95% CI: 0.73%–1.46%) when only the 69 datasets with a more conservative time lag of ≥90 days between the two episodes were considered2–6,8,10,12,13,15,16,18–23,25,26,36,42–44,46–50,52–56,59,61–65,67–69,72–84,86,87,89,91–96,98,101,103,105–107 and it slightly varied by reinfection definition criteria (0.93% vs 1.01% when considering studies with high vs low risk of misclassification). The risk of reinfection was higher among health care workers as compared to the general population (1.20% vs 0.90), and among females (0.79% vs 0.55% among males), although these estimates showed largely overlapping confidence intervals. Conversely, the reinfection rate varied widely by vaccination status: a lower likelihood of reinfection was observed in the studies where 100% of the subjects received at least one vaccine dose (0.32% vs. 0.77% among the unvaccinated—Table 1). Overall, the pooled rates of reinfection were higher in US-based studies (1.08%; 95% CI: 0.93%–1.25%) than in studies performed in Europe (0.63%; 95% CI: 0.44%–0.84%), or in Asia (0.77%; 95% CI: 0.50%–1.10%).

When the analyses were stratified by time from the primary infection, the highest reinfection rates were observed after 6–11 months from the first episode, reaching 1.12% (95% CI: 0.57%–1.82%); the pooled rates then substantially decreased to 0.66% after ≥12 months from the first infection.

Finally, when the analyses were stratified by predominant strain, a sharply rising trend was observed with the emergence of new variants: the pooled reinfection rates were 0.57% (95% CI: 0.28%–0.94%) in the studies providing specific data on the Alpha wave; the rates rose to 1.25%
with the Delta strain and peaked to 3.31% (95% CI: 1.15%–6.53%) during the first three months of the Omicron wave.

In the 59 available datasets2,3,5,6,10,16–22,25–27,36,44,46–59,63–67,69,71–74,79,82,84–87,90,93–95,99–104 a total of 1380 severe COVID-19 diseases were diagnosed among 5,006,604 subjects with a previous infection, corresponding to a pooled rate of 0.02% (95% CI: 0.00%–0.04%—Table 1). This rate did not substantially vary when only the studies with longer time lag were considered, while it increased—still, however, remaining below 0.1%—when only the studies that used CDC criteria to define reinfections were included (summary rate 0.07%; 0.04%–0.10%). The risk of severe COVID-19 was always below 0.1% with any predominant strain and in the studies where 100% of the subjects received at least one vaccine dose (0.01% vs 0.10% among the unvaccinated—Table 1).

Finally, in the 54 datasets that provided data for the analysis of very severe/lethal COVID-19,2,3,5,6,10,16–22,25–27,44,47–59,64–66,69,71–73,79,81,82,84–87,92,94,95,99–104 a total of 199 events were recorded among 3,574,793 previously infected individuals, corresponding to a pooled rate of 0.02% (0.01%–0.03%), which did not differ by time lag or definition criteria.

4 | DISCUSSION

The main findings of this meta-analysis, based upon the pooled results of 91 cohort studies, including more than 15 million individuals who were previously infected with SARS-CoV-2 provide some solid confirmations, and a few updates: (a) after an average of twelve months of follow-up, the overall risk of reinfection approaches 1%, with no substantial differences across genders, exposure risk and definition criteria; (b) the likelihood of reinfection increased considerably over time, particularly with the spread of new highly transmissible variants, peaking during the first three months of the Omicron wave; (c) the summary rates of severe or lethal COVID-19 were still very
TABLE 1  Pooled rates of reinfection⁴, severe COVID-19 disease⁵ and very severe/lethal COVID-19⁶ among subjects with a previous SARS-CoV-2 infection, overall and according to reinfection definition criteria, gender, exposure risk (type of population), time lag between first infection and second episode, vaccination status and predominant strain

| Outcomes                                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|-------------------------------------------|-------------|-------------------------|--------------------------|------|
| Reinfection                               |             |                         |                          |      |
| Estimated pooled rate                     | 2-10,12,13,15-27,36,38,42-107 | 94 (158,478/15,034,624) | 0.97 (0.71–1.27) | 99   |
| Including only studies with time lag ≥90 days⁵ | 3-6,8-10,12,18-23,25,26,36,42-44,46-50,52,56,59,61-65,67,72-84,86,87,89,91-96,98,101,103,105-107 | 69 (142,596/11,895,618) | 1.07 (0.73–1.46) | 99   |

Stratified analyses

1. By reinfection definition criteria

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| Probable reinfection (high risk of misclassification)⁶ | 2,4,5,7-9,12,15,17,18,21,25,27,38,42,46,47,51-53,55,57,60,62,64-66,69,70,73,74-76,83,85,87,89,92,93,95-98,101,103-107 | 56 (155,051/12,868,418) | 0.93 (0.64–1.28) | 99   |
| Confirmed reinfection (low risk of misclassification)⁹ | 10,16,19,20,22-24,26,36,44,45,48-50,54,56,58,59,68,71,72,75,84,86,89-91,94,99,100,102 | 38 (3427/2,166,206) | 1.01 (0.61–1.49) | 99   |

2. By gender

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| Males           | 5,9,18,22,36,42,47,49-51,55-57,59,65-69-72,74,82,86,87,95,96,101,103,105,107 | 32 (47,969/2,634,694) | 0.55 (0.14–1.16) | 99   |
| Females         | 5,9,18,22,36,42,47,49-51,55-57,59,65-69-72,74,82,86,87,95,96,101,103,105,108 | 32 (70,099/7,695,452) | 0.79 (0.18–1.69) | 99   |

3. By exposure risk

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| General population | 5-7,10,12,13,16-23,25-27,29,40,60,63-64,67,69,72,75,77,86,98,100,103,105 | 67 (157,806/1,499,706) | 0.90 (0.61–1.24) | 99   |
| Health care workers | 2,8,9,15,17,24,26,36,42-49 | 27 (672/37,598) | 1.20 (0.59–1.98) | 92   |

4. By length of follow-up (time between first infection and reinfection)

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| Less than 6 months (<183 days) | 3,6,7,15-17,19,20,22-25,27,38,46,49,57,63,67,70,71,73,75,77,83,84,88,93,97,98,107 | 34 (35,487/8,123,293) | 0.58 (0.50–0.68) | 99   |
| 6-11 months (183–364 days) | 2,9,10,18,21,26,36,42,44,45,50-52,54,59,61,65,71,79,88,90,91,94,95,102,103,106 | 27 (314/1,987,532) | 1.12 (0.57–1.82) | 99   |
| 12 or more months (≥365 days) | 8,55,71 | 4 (362/48,384) | 0.66 (0.50–0.84) | 24   |

5. By vaccination status

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| Unvaccinated     | 49-51,55,57,63,68,71,93,97,98,102,104 | 14 (12,408/3,116,047) | 0.74 (0.57–0.93) | 99   |
| Vaccination campaign covering 25–50% of the sample | 36,47,54,56,74,79,83,94,105 | 9 (21,800/5,727,836) | 0.95 (0.45–1.64) | 99   |
| Vaccination campaign covering 100% of the sample | 3,71 | 3 (588/248,049) | 0.32 (0.11–0.64) | 99   |

6. By predominant viral strain⁹

|                  | Study ref.⁸ | N. datasets⁹ (raw data) | Pooled rates, % (95% CI) | I, % |
|------------------|-------------|-------------------------|--------------------------|------|
| Alpha (B.1.1.7) | 38,47,49,71,87,90,104 | 11 (5566/1,209,861) | 0.57 (0.28–0.94) | 99   |
| Delta (B.1.617.2) | 30,45,52,53,56,65,70,73,74,79,80,83,89,93,106 | 15 (26,583/5,225,116) | 1.25 (0.97–1.55) | 100  |
| Omicron (B.1.1.529) | 66,71,88,91,96 | 5 (112,928/3,854,961) | 3.31 (1.15–6.53) | 99   |

(Continues)
### Outcomes Study ref.\(^g\)

| Outcomes                        | Study ref.\(^g\) | N. datasets\(^e\) (raw data) | Pooled rates, % (95% CI) | I, % |
|---------------------------------|------------------|-------------------------------|--------------------------|------|
| 7. By geographic area           |                  |                               |                          |      |
| Europe                          | 2,4,10,12,15,17,18,21,24,26,36,38,44,46–51,58,66,69,71,72,75,81,85–88,91–93,95,99,102 | 46 (17,186/3,263,398) | 0.63 (0.44–0.84) | 100  |
| US                              | 20,22,23,25,42,43,57,59,63,67,77,79,82–84,89,90,97,98,103,105–108 | 24 (28,136/6,119,540) | 1.08 (0.93–1.25) | 99   |
| Asia                            | 3,16,19,27,45,52–54,56,60,62,64,65,70,73,74,100,101 | 18 (8161/1,063,517) | 0.77 (0.50–1.10) | 99   |
| Severe COVID-19 disease\(^b\)   |                  |                               |                          |      |
| Estimated pooled rate           | 2,3,5,6,10,16–22,25–27,36,44,46–59,63–67,69,71–74,79,82–84,87,90,93–95,99–104 | 59 (1380/5,006,604) | 0.02 (0.00–0.04) | 98   |
| Including only studies with time lag ≥90 days\(^b\) | 3,5,6,10,18–22,25,26,36,44,46–50,52–56,59,63–65,67,69,72–74,79,82,84,86,87,90,93–95,103 | 44 (1322/4,785,454) | 0.02 (0.00–0.06) | 99   |

### Stratified analyses

1. By reinfection definition criteria

| Probable reinfection (high risk of misclassification)\(^d\) | 2,5,17,18,21,25,27,46,47,51–53,55,57,64–66,69,73,74,79,82,85,87,93,95,101,103,104 | 30 (1282/2,907,510) | 0.05 (0.01–0.10) | 99   |
| Confirmed reinfection (low risk of misclassification)\(^e\) | 3,6,10,16,19,20,22,26,36,44,46–50,54,56,59,63,67,71,72,84,86,87,90,94,98,100,102 | 29 (98/2,099,094) | 0.07 (0.04–0.10) | 93   |

2. By vaccination status

| Unvaccinated              | 49–51,55,57,63,71,93,102,104 | 11 (164/1,066,987) | 0.10 (0.04–0.19) | 86   |
| Vaccination campaign covering 25–50% of the sample | 36,47,54,56,74,79,94 | 7 (43/2,371,936) | 0.00 (0.00–0.01) | 95   |
| Vaccination campaign covering 100% of the sample | 3,48,71 | 3 (17/248,049) | 0.01 (0.00–0.03) | 93   |

3. By predominant viral strain\(^f\)

| Alpha (B.1.1.7)     | 3,17,47,48,71,8790,104 | 9 (88/950,690) | 0.03 (0.01–0.06) | 92   |
| Delta (B.1.617.2)   | 3,5,53,56,57,73,74,79,93 | 8 (1087/1,862,216) | 0.07 (0.00–0.20) | 100  |
| Omicron (B.1.1.529) | 66,71 | 2 (19/64,522) | 0.03 (0.02–0.04) | –    |

4. Very severe/lethal COVID-19\(^c\)

| Estimated pooled rate | 2,3,5,6,10,16–22,25–27,36,44,46–59,63–67,69,71–73,79,81,82–84,87,92,94,95,99–104 | 54 (199/3,574,793) | 0.02 (0.00–0.03) | 91   |
| Including only studies with time lag ≥90 days\(^b\) | 3,5,6,10,18–22,25,26,36,44,46–50,52–56,59,64,65,67,69,72,73,79,81,82,84,86,87,94,95,101,103 | 39 (183/3,392,229) | 0.02 (0.01–0.03) | 93   |
TABLE 1 (Continued)

| Outcomes                                      | Study ref. | N. datasets (raw data) | Pooled rates, % (95% CI) | I, % |
|-----------------------------------------------|------------|------------------------|--------------------------|------|
| Stratified analyses                           |            |                        |                          |      |
| 1. By reinfection definition criteria         |            |                        |                          |      |
| Probable reinfection (high risk of misclassification) | 2,5,7,12,13,23,24,45,46,49,52,53,54,55,56,57,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104 | 28 (171/1,490,266) | 0.02 (0.01–0.03) | 92 |
| Confirmed reinfection (low risk of misclassification) | 3,6,9,10,11,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102 | 26 (28/2,084,527) | 0.02 (0.01–0.03) | 92 |

Notes: Raw data show the number of subjects with each outcome upon the total number of included subjects. Data from single studies have been combined using proportion meta-analysis (random-effect model).

Abbreviations: CI, confidence interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus.

Asymptomatic infection or mild disease, defined as fever or malaise plus at least one of the following: sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis and diarrhoea with no hospital admission.

Severe disease, requiring hospital admission, not in an intensive care unit.

Very severe or lethal disease, requiring admission in an intensive care unit and/or causing death.

A probable reinfection was defined as a new positive RT-PCR sample ≥45 days after a proven baseline SARS-CoV-2 infection (either assessed through a first positive nasopharyngeal swab or a positive serology—detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay—ELISA), with no intermediate negative RT-PCR sample or viral genomic sequencing.

A confirmed reinfection was defined as a new positive RT-PCR sample ≥45 days after a proven baseline SARS-CoV-2 infection (either assessed through a first positive nasopharyngeal swab or a positive serology—detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay—ELISA), with ≥1 intermediate negative RT-PCR sample and/or a confirmation of infection with two different phylogenetic strains, obtained through viral genomic sequencing.

Alpha wave: from September 2020 (first detection: UK; worldwide geographic distribution); Delta wave: from December 2020 (first detection: India; worldwide geographic distribution); Omicron wave: from December 2021 (first detection: South Africa; worldwide geographic distribution; Available in: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html). For Italy: Omicron wave started from 28 December 2021 when the proportion of Omicron variant in the available positive swabs was higher than 50%. Available in: Italian National Institute of Health (2021) Stima della prevalenza delle varianti VOC (Variants of Concern) in Italia: beta, gamma, delta, omicron e altre varianti di SARS-CoV-2. (https://www.iss.it/documents/20260/0/Report_flashVariante_14gennaio22.pdf/b44b1a7d-a0c1-67fd-44b7-34c8b775c088t=1642162662435).

Four studies contributed with more than one dataset; thus, the number of references does not always match the number of datasets included in each analysis (see methods for further details).

Excluding studies with a time lag <90 days between two positive RT-PCR tests, with or without an intermediate negative PCR/viral genomic confirmation between the first and second episode.
FIGURE 2 Proportion meta-analysis of the risk of SARS-CoV-2 reinfection among previously infected subjects.
low, ranging from 2 to 7 out of 10,000 subjects according to the adopted definition criteria, and were not affected by strain predominance; (d) the pooled risk of reinfection was significantly lower among the subjects that received one or more vaccine doses, versus the unvaccinated.

A low risk of reinfection and a very low risk of severe or lethal COVID-19 for those who recovered from a primary infection were reported in the vast majority of the published studies, as well in the available systematic reviews. Most of the available information, however, included data preceding the emergence of the Omicron wave, or relied upon very preliminary data. Importantly, we expanded the existing evidence with the analysis of a very large database across different geographic areas, including reinfections up to the first three months of the Omicron wave, and providing confirmation of a substantially increased risk of reinfection, temporally linked with the emergence of this variant.

In the context of the pandemic, there has been debate on the health policies to adopt for the population of previously infected subjects. On one side, the restriction policies and vaccination requirements have been less strict in several countries, in consideration of their low/very low-risk profile. On the other side, concerns on the appropriateness of such policies remained, because the duration of the natural immunity was unknown and, more recently, because of the spread of the Omicron variant, which showed a marked increase in the number of infections and hospitalizations as a result of a very high level of community transmission. This led some countries to establish a time limit from the first infection, after which one or two doses of vaccine were requested. However, data are strongly needed to support such policies, since no study evaluated the risk of reinfection after 12 months of follow-up, during the Omicron wave, and no information was available on the potential impact of vaccination after the first infection.

Some of the findings of our analysis are reassuring, supporting less strict, targeted policies for the subjects who recovered from a previous infection: the rates of severe or lethal COVID-19 were extremely low, suggesting that the health risk and impact on the health services of these subjects, during the next phases of the SARS-CoV-2 pandemic, might be very limited. On the other side, however, we observed a concerning, marked increase in the reinfection rates during the Omicron wave, and a significantly lower risk of reinfection among the vaccinated subjects, thus vaccinating also this population may definitely play an important role to control the pandemic. It remains to be considered that, if during the Omicron wave the risk of a secondary severe disease or death will remain close to zero despite the large increase of reinfections, the risk-benefit profile of multiple vaccine doses for this population will have to be carefully evaluated. Unfortunately, of the five studies providing data on the Omicron wave, only two (although based upon a very large sample) specifically assessed the number of severe COVID-19. On one side, the very low pooled rates of hospitalization recorded even after Omicron surge are reassuring. On the other side, however, such findings require confirmation, and the large increase in reinfections during the first months of Omicron predominance is a matter of serious concern.

Interestingly, and in line with previous studies, we found some degree of variation in reinfection rates across geographical areas. Besides the genetic pattern, the main potential explanations include differences in the detection process caused by the adoption of diverse testing policies, diagnostic methods and health-seeking behaviours, and the fact that countries have been sequentially hit by different variants of SARS-CoV-2. Indeed, the mutual combination of these factors may explain, at least in part, the spatial unevenness of SARS-CoV-2 spread, which has been observed even at a sub-national level.

The study has some limitations that should be considered when interpreting the results. On one side, the incidence of reinfection could have been overestimated in several of the included studies, which confirmed the reinfection status adopting less stringent definition criteria. On the other side, the rate of reinfection may have been underestimated in most studies, as the existing monitoring systems could not detect all of the asymptomatic re-infections. Indeed, many subjects might not have sought medical attention because of mild or even sub-clinical disease. To address this potential detection bias, a sensitivity analysis based upon the average number of PCR tests performed, taken as a proxy of health-seeking behaviour, may have increased the precision of our estimates. Unfortunately, these data were not available. Notably, however, the pooled estimates of reinfection incidence were comparable in the general population and health care workers, who have often been subjects to continuous testing.

Second, individual-participant data were available for one study only; thus, we could not perform stratified analyses based upon age, concomitant immunological conditions potentially affecting the risk of reinfection or, as above said, health-seeking behaviours.

Acknowledging these caveats, the present meta-analysis showed that, among more than 15 million previously infected individuals, the overall rates of reinfection showed an increasing trend along with the emergence of Omicron variant, although the risk of severe or lethal COVID-19 was still very low, and vaccination may be effective in reducing the risk of reinfection. Further data from studies with even longer follow-up, carried out after the first months of the Omicron wave, and assessing whether the risk of severe or lethal COVID-19 will vary...
with the spread of new variants, are inevitably needed to guide the future public health policies targeted to the large population of subjects who recovered from a SARS-CoV-2 infection.

**AUTHOR CONTRIBUTIONS**

All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. MEF and LM conceived and designed the systematic review and were involved in all phases of the study. MEF, CAM and VB designed and implemented the search strategy. CAM, VB and ER extracted the data. MEF and LM wrote the manuscript, which was revised by CDV and PV. All authors were involved in the critical revision of the intellectual content of the manuscript.

**ACKNOWLEDGEMENT**

Open Access Funding provided by Universita degli Studi di Bologna within the CRUI-CARE Agreement.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**FUNDING INFORMATION**

This research received no external funding.

**DATA AVAILABILITY STATEMENT**

The data presented in this study are available upon reasonable request from the corresponding author.

**ORCID**

Cecilia Acuti Martellucci [https://orcid.org/0000-0002-4308-2144]
Valentina Baccolini [https://orcid.org/0000-0002-7873-7817]
Lamberto Manzoli [https://orcid.org/0000-0002-8129-9344]

**REFERENCES**

1. To KK, Hung IF, Ip JD, et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. *Clin Infect Dis*. 2021;73(9):e2946-e2951. doi:10.1093/cid/ciaa1275
2. Abo-Leyah H, Gallant S, Cassidy D, et al. The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. *ERJ Open Res*. 2021;7(2). 00080-2021 [pii]. doi:10.1183/23120541.0080-2021
3. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. *JAMA*. 2021;326(19):1930-1939. doi:10.1001/jama.2021.19623
4. Breathnach AS, Duncan CJA, Bouzidi KE, et al. Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. *J Infect*. 2021;83(2):237-279. doi:10.1016/j.jinf.2021.05.024
5. Breathnach AS, Riley PA, Cotter MP, Houston AC, Habibi MS, Planche TD. Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. *J Infect*. 2021;82(4):e11-e12. doi:10.1016/j.jinf.2021.01.005
6. Brouqui P, Colson P, Melenotte C, et al. COVID-19 re-infection. *Eur J Clin Invest*. 2021;51(5):e13357. doi:10.1111/eji.13357
7. Clarke CL, Prendek M, Dhtia A, et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. *Kidney Int*. 2021;99(6):1470-1477. doi:10.1016/j.kint.2021.03.009
8. Davido B, De Truchis P, Lawrence C, et al. SARS-CoV-2 reinfections among hospital staff in the greater Paris area. *J Travel Med*. 2021;28(4). taab058 [pii]. doi:10.1093/jtm/taab058
9. Dobano C, Ramirez-Morros A, Alonso S, et al. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. *BMC Med*. 2021;19(1):155. doi:10.1186/s12916-021-02032-2
10. Fabianova K, Kynel J, Vlckova I, et al. COVID-19 reinfections. *Epidemiol Mikrobiol Imunol*. 2021;70(1):62-67. Reinfekte covidem-19. doi: 126636 [pii].
11. Flacco ME, Acuti Martellucci C, Soldato G, et al. Rate of reinfections after SARS-CoV-2 primary infection in the population of an Italian province: a cohort study. *J Public Health (Oxf)*. 2021. fdab346 [pii]. doi:10.1093/pubmed/fdb346. Online ahead of print.
12. Gautret P, Houhamdi L, Nguyen NN, Hoang VT, Giraud-Gatineau A, Raoult D. Does SARS-CoV-2 re-infection depend on virus variant? *Clin Microbiol Infect*. 2021;27(9):1374-1375. doi:10.1016/j.cmi.2021.06.029
13. Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: re-infections versus breakthrough infections. *MedRxiv*. 2021. doi:10.1101/2021.08.24.21262415
14. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
15. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *J Infect*. 2021;82(4):e29-e30. doi:10.1016/j.jinf.2020.12.023
16. Hussein NR, Rashad BH, Almizori LA, et al. The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan region of Iraq. *Medit Intern J*. 2021;38(1):e2021035. doi:10.4084/MJHID.2021.035
17. Krutikov M, Palmer T, Tut G, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. *J Epidemiol Microbiol Micronutral*. 2021;70(1):62-67. Reinfekce covidem-19. doi: 126636 [pii].
18. Leidi A, Koegler F, Dumont R, et al. Risk of reinfection after SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. *Clin Infect Dis*. 2021;82(4):e11-e12. doi:10.1016/j.jinf.2021.01.005
19. Mukherjee A, Anand T, Agarwal A, et al. SARS-CoV-2 re-infection: development of an epidemiological definition from India. *Epidemiol Infect*. 2021;149:e82. doi:10.1017/S0950268821000662
20. Peltan ID, Beesley SJ, Webb BJ, et al. Evaluation of potential COVID-19 recurrence in patients with late repeat
positive SARS-CoV-2 testing. PloS One. 2021;16(5):e0251214. doi:10.1371/journal.pone.0251214

21. Pilz S, Chakeri A, Ioannidis JP, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51(4):e13520. doi:10.1111/euci.13520

22. Qureshi AI, Baskett WI, Huang W, Lobanova I, Naqvi SH, Shyu CR. Re-infection with SARS-CoV-2 in patients undergoing serial laboratory testing. Clin Infect Dis. 2022;74(2):294-300. doi:10.1093/cid/ciab345

23. Rennert L, McMahon C. Risk of SARS-CoV-2 reinfection in a university student population. Clin Infect Dis. 2022;74(4):719-722. doi:10.1093/cid/ciab544

24. Sanchez-Montalva A, Fernandez-Naval C, Anton A, et al. SARS-CoV-2 re-infection among patients who previously tested positive for coronavirus disease 2019: a retrospective cohort study. Clin Infect Dis. Nov 16, 2021;73(10):1882-1886. doi:10.1093/cid/ciab234

25. Sheehan MM, Reddy AJ, Rothenberg MB. Reinfection rates among patients who previously tested positive for coronavirus disease 2019: a retrospective cohort study. Clin Infect Dis. Nov 16, 2021;73(10):1882-1886. doi:10.1093/cid/ciab234

26. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021;181(10):1407-1408. doi:10.1001/jamainternmed.2021.2959

27. Zare F, Teimouri M, Khorasavi A, et al. COVID-19 re-infection in Shahroud, Iran: a follow-up study. Epidemiol Infect. 2021;149:e159. doi:10.1017/S095026882100087X

28. Yahav D, Yelin D, Eckerle I, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021;27(3):315-318. doi:10.1016/j.cmi.2020.11.028

29. Biswas S, Mahmud S, Mita MA, et al. The emergence of SARS-CoV-2 variants with a lower antibody response: a genomic and clinical perspective. Front Med (Lausanne). 2022;9:825245. doi:10.3389/fmed.2022.825245

30. Akkiz H. The biological functions and clinical significance of SARS-CoV-2 variants of Concern. Front Med (Lausanne). 2022;9:849217. doi:10.3389/fmed.2022.849217

31. Pilz S, Theiler-Schweiz V, Trummer C, Krause R, Ioannidis JPA. Risk of SARS-CoV-2 reinfection during the second wave of pandemic in India: an observational study. Int J Infect Dis. 2022;118:95-103. doi:10.1016/j.ijid.2022.02.037

32. Dimeglio C, Herin F, Eckerle I, et al. Antibody status and incidence of SARS-CoV-2 infection in healthcare workers. N Engl J Med. 2021;384(6):533-540. doi:10.1056/NEJMoa2034545

33. Common Investigation Protocol for Investigating Suspected SARS-CoV-2 Reinfection. 2020.

34. Jain VK, Iyengar K, Garg R, Vaishya R. Elucidating reasons of COVID-19 re-infection and its management strategies. Diabetes Metab Syndr. 2021;15(3):1001-1006. doi:10.1016/j.dsx.2021.05.008

35. Al-Tawfiq JA, Rabaan AA, Al-Omari A, Al Mutair A, Al-Qahtani M, Tirupathi R. Learning from SARS and MERS: COVID-19 reinfection where do we stand? Travel Med Infect Dis. 2021;41:102024. doi:10.1016/j.tmtd.2021.102024

36. Akinbami LJ, Biggerstaff BJ, Chan PA, McGibbon E, Pathela P, Petersen LR. Reinfection with SARS-CoV-2 among previously infected healthcare personnel and first responders. Clin Infect Dis. 2021. ciab952 [pii]. doi:10.1093/cid/ciab952. Online ahead of print.

37. Dhumal S, Patil A, More A, et al. SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: an observational study. Int J Infect Dis. 2022;118:95-103. doi:10.1016/j.ijid.2022.02.037

38. Dimeglio C, Herin F, Miedouge M, Martin-Blondel G, Soulant JM, Izopet J. Protection of healthcare workers against severe acute respiratory syndrome coronavirus 2 in healthcare workers and first responders. J Infect Dis. 2021;224(11):1873-1877. doi:10.1093/infdis/jiaf504

39. Comelli A, Consonni D, Lombardi A, et al. Nasopharyngeal testing among healthcare workers (HCWs) of a large University Hospital in Milan, Italy during two epidemic waves of COVID-19. International Journal of Environmental Research and Public Health. 2021;18(16). 8748 [pii]. doi:10.3390/ijerph18168748

40. Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:103561. doi:10.1016/j.ebiom.2021.103561

41. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207-1220. doi:10.1056/NEJMoa2118691

42. Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Healthy Longev. 2021;2(12):e811-e819. doi:10.1016/S2666-7568(21)00253-1

43. Kohler P, Gusewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. BMC Med. 2021;19(1):270. doi:10.1186/s12916-021-02144-9

44. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207-1220. doi:10.1056/NEJMoa2118691

45. Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Healthy Longev. 2021;2(12):e811-e819. doi:10.1016/S2666-7568(21)00253-1

46. Kohler P, Gusewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. BMC Med. 2021;19(1):270. doi:10.1186/s12916-021-02144-9

47. Leidi A, Berner A, Dumont R, et al. Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic
surge: a cohort study. Occup Environ Med. 2022;79(2):116-119. doi:10.1136/oemed-2021-107924
52. Malhotra S, Mani K, Lodha R, et al. SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health Care Workers in new Delhi, India. JAMA Netw Open. 2022;5(1):e214220. doi:10.1001/jamanetworkopen.2021.42210
53. Murugesan M, Mathews P, Paul H, Karthik R, Mammen JJ, Rupali P. Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. PLoS One. 2022;17(5):e0268797. doi:10.1371/journal.pone.0268797
54. Nisha B, Dakshinamoorthy K, Padmanaban P, Jain T, Neelavarnan M. Infection, reinfection, and postvaccination incidence of SARS-CoV-2 and associated risks in healthcare workers in Tamil Nadu: a retrospective cohort study. J Family Community Med. 2022;29(1):49-55. doi:10.4103/jfcm.jfcm_399_21
55. Racine E, Boivin G, Longtin Y, et al. The REinfection in workers. 2022;12(1):1438. doi:10.1038/s41598-022-05325-5
56. Rahman S, Rahman MM, Miah M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022;12(1):1438. doi:10.1038/s41598-022-05325-5
57. Schuler CF, Gherasim C, O'Shea K, et al. Mild SARS-CoV-2 illness is not associated with reinfections and provides persistent spike, nucleocapsid, and virus-neutralizing antibodies. Microbiol Spectr. 2021;9(2):e0008721. doi:10.1128/Spectrum.00087-21
58. Wack M, Pere H, Demory-Guinet N, et al. No SARS-CoV-2 reinfection and serology dynamics in a cohort of Canadian healthcare workers. J Family Community Med. 2022;29(1):49-55. doi:10.4103/jfcm.jfcm_399_21
59. Racine E, Boivin G, Longtin Y, et al. The REinfection in workers. 2022;12(1):1438. doi:10.1038/s41598-022-05325-5
60. Ahmad HA, Khan H, Shahzad M, Haq ZU, Harakeh S, M. SARS-CoV-2 reinfection associates with unstable housing and occurs in the presence of antibodies. Clin Infect Dis. 2021;cbi940 [pii]. doi:10.1093/cid/cbi940. Online ahead of print.
61. Akpan GE, Bawo L, Amo-Addae M, et al. COVID-19 reinfection among health-care workers: a prospective hospital-wide screening during the first and second waves in Paris. J Clin Virol. 2021;145:104999. doi:10.1016/j.jcv.2021.104999
62. Wilkins JT, Hirschhorn LR, Gray EL, et al. Serologic status and SARS-CoV-2 infection over 6 months of follow up in healthcare workers in Chicago: a cohort study. Infect Control Hosp Epidemiol. 2021;1-9. doi:10.1017/ice.2021.367. Online ahead of print.
63. Armstrong JN, Campbell L, Rabatsky-Her T, Leung V, Parikh S. Repeat positive SARS-CoV-2 RNA testing in nursing home residents during the initial 9 months of the COVID-19 pandemic: an observational retrospective analysis. Lancet Reg Health Am. 2021;3:100054. doi:10.1016/j.ljana.2021.100054
64. Arslan F, Isik Goren B, Baysal B, Vahaboglu H. Is vaccination necessary for COVID-19 patients? A retrospective cohort study investigating reinfection rates and symptomatology in a tertiary hospital. Expert Rev Vaccines. 2022;21(2):249-252. doi:10.1080/14760584.2022.2012457
65. Arslan Y, Akgul F, Sevim B, Varol ZS, Tekin S. Re-infection in COVID-19: do we exaggerate our worries? Eur J Clin Invest. 2022;52(6):e13767. doi:10.1111/ejc.13767
66. Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022;22(7):967-976. doi:10.1016/S1473-3099(22)00154-2
67. Bean DJ, Monroe J, Turcincovic J, Moreau Y, Connor JH, Sagar M. SARS-CoV-2 reinfection associates with unstable housing and occurs in the presence of antibodies. Clin Infect Dis. 2021; cbi940 [pii]. doi:10.1093/cid/cbi940. Online ahead of print.
68. Cohen C, Kleyhnans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect Dis. 2022;22(6):821-834. doi:10.1016/S1473-3099(22)00069-X
69. Coppola A, Buonerba C, Cardinale D, et al. Durability of humoral immune responses to SARS-CoV-2 in citizens of Ariano Irpino (Campania, Italy): a longitudinal observational study with an 11.5-month follow-up. Front Public Health. 2021;9:801609. doi:10.3389/fpubh.2021.801609
70. Doke P, Gothankar JS, Doke PP, et al. Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection. Microbes Infect. 2022;24(4):104979. doi:10.1016/j.micinf.2022.104979
71. Flacco ME, Soldato G, Aciuti Martellucci C, et al. Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study. Front Public Health. 2022;10:884121. doi:10.3389/fpubh.2022.884121
72. Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41(7):1490-1501. doi:10.1007/s10875-021-01083-7
73. Gazit S, Shlezinger R, Perez G, et al. The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine: a retrospective cohort study. Ann Intern Med. 2022;175(5):674-681. doi:10.7326/M21-4130
74. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201-2212. doi:10.1056/NEJMoa2118946
75. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021;6(5):e335-e345. doi:10.1016/S2468-2667(21)00055-4
76. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2022;397(10280):1204-1212. doi:10.1016/S0140-6736(21)00575-4
77. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366
87. Mensah AA, Campbell H, Stowe J, et al. Risk of SARS-CoV-2 and protection from symptomatic second infection in children. J Infect. 2021;82(6):276-316. doi:10.1016/j.jinf.2021.03.020

88. Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of a second dose of an mRNA vaccine against SARS-CoV-2 in solid-organ transplant recipients: incidence density and viral reinfections. Front Cell Infect Microbiol. 2022;12:809407. doi:10.3389/fcimb.2022.809407

90. Morris CP, Luo CH, Sachithanandham J, et al. Large scale SARS-CoV-2 molecular testing and genomic surveillance reveals prolonged infections, protracted RNA shedding, and viral reinfections. Front Cell Infect Microbiol. 2022;12:809407. doi:10.3389/fcimb.2022.809407

93. Nitipir C, Parosanu AI, Olaru M, et al. Infection and reinfection with SARS-CoV-2 in cancer patients: a cohort study. Exp Ther Med. 2022;23(6):399. doi:10.3892/etm.2022.11326

94. Pampa-Espinoza L, Padilla-Rojas C, Silva-Valencia J, et al. Confirmed severe acute respiratory syndrome coronavirus 2 reinfections after a second wave with predominance of lambda in Lima and Callao, Peru. Open Forum Infect Dis. 2022;9(6):ofac134. doi:10.1093/ofid/ofac134
106. Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Association of Severe Acute Respiratory Syndrome Coronavirus 2 vaccination or a prior positive test result in adolescents during the Delta variant surge in Kentucky. J Pediatr. 2022. doi:10.1016/j.jpeds.2022.05.034. Online ahead of print.

107. Rivelli A, Fitzpatrick V, Blair C, Copeland K, Richards J. Incidence of COVID-19 reinfection among midwestern healthcare employees. PLoS One. 2022;17(1):e0262164. doi:10.1371/journal.pone.0262164

108. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for reinfection after SARS-CoV-2: a living, rapid review for American College of Physicians Practice Points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. 2022;175(4):547-555. doi:10.7326/M21-4245

109. Mao Y, Wang W, Ma J, Wu S, Sun F. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021;135(2):145-152. doi:10.1097/CM9.0000000000001892

110. Chivese T, Matizanadzo JT, Musa OAH, et al. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery—a comprehensive systematic review and meta-analysis. Pathog Glob Health. 2022;116(5):269-281. doi:10.1080/20477724.2022.2029301

111. Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: a systematic review and meta-analysis. J Med Virol. 2022;94(1):44-53. doi:10.1002/jmv.27281

112. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(1):12-14. doi:10.1016/S1473-3099(21)00676-9

113. European Council. Council Recommendation on a Coordinated Approach to Facilitate Safe Free Movement during the COVID-19 Pandemic and Replacing Recommendation (EU) 2020/1475. In: Council E, ed. Brussels. European Union; 2022.

114. Italian Government. Misure urgenti per il contenimento della diffusione dell’epidemia da COVID-19 e disposizioni in materia di sorveglianza sanitaria. (21G00258). In: Government I, ed. 2021. https://www.governo.it/leggi-testo/102928

115. Dolgin E. Is one vaccine dose enough if you’ve had COVID? What the science says. Nature. 2021;595(7866):161-162. doi:10.1038/d41586-021-01609-4

116. Majeed A. London is an important barometer for the omicron wave in the United Kingdom. BMJ. 2022;376:e40. doi:10.1136/bmj.o42

117. WHO. Enhancing response to omicron SARS-CoV-2 variant: technical brief and priority actions for member states. 2022. Enhancing Response to Omicron SARS-CoV-2 Variant. January 21, 22. Accessed January 16, 2022. https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states

118. Willyard C. What the omicron wave is revealing about human immunity. Nature. 2022;602(7895):22-25. doi:10.1038/d41586-022-00214-3

119. Italian Ministry of Health. Aggiornamento indicazioni sulla Vaccinazione dei soggetti che hanno avuto un’infezione da SARS-CoV-2. In: Italian Ministry of Health, ed. 2021.

120. Prajapat M, Handa V, Sarma P, et al. Update on geographical variation and distribution of SARS-CoV-2: a systematic review. Indian J Pharmacol. 2021;53(4):310-316. doi:10.4103/ijp.ijp_483_21

121. Ascani A, Faggian A, Montresor S. The geography of COVID-19 and the structure of local economies: the case of Italy. J Reg Sci. 2021;61(2):407-441. doi:10.1111/jors.12510

122. Callaway E. Are COVID surges becoming more predictable? New omicron variants offer a hint. Nature. 2022;605(7909):204-206. doi:10.1038/d41586-022-01240-x

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Flacco ME, Acuti Martellucci C, Baccolini V, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. Eur J Clin Invest. 2022;00:e13845. doi: 10.1111/ect.13845